Vedolizumab: Real-life outcomes to therapy in ulcerative colitis

被引：0

作者：

Pulusu, S. S. R. ^{[1
]}

Krishnaprasad, K. ^{[2
,7
,9
]}

Cheng, D. ^{[3
]}

Mogilevski, T. ^{[6
]}

Flanagan, E. ^{[7
]}

Parthasarathy, N. ^{[8
]}

Wu, C. ^{[10
]}

Prosser, R. ^{[12
]}

Sawyer, E. ^{[11
]}

Rizvi, Q-U-A ^{[13
]}

Taylor, K. ^{[9
]}

Sewell, K. ^{[4
]}

Cooke, S. ^{[5
]}

Mahy, G. ^{[5
]}

Radford-Smith, G. ^{[2
,4
]}

Sparrow, M. ^{[9
]}

Andrews, J. ^{[13
]}

Connor, S. ^{[11
]}

Bampton, P. ^{[12
]}

Ghaly, S. ^{[10
]}

Van Langenberg, D. ^{[8
]}

Bell, S. ^{[7
]}

De Cruz, P. ^{[6
]}

Begun, J. ^{[1
,3
]}

Lawrance, I.

机构：

[1] St John God Hosp, Ctr Inflammatory Bowel Dis, Perth, WA, Australia

[2] QIMR Berghofer Med Res Inst, Inflammatory Bowel Dis Res Grp, Brisbane, Qld, Australia

[3] Mater Hosp, Dept Gastroenterol, Brisbane, Qld, Australia

[4] Royal Brisbane & Womens Hosp, Dept Gastroenterol, Brisbane, Qld, Australia

[5] Townsville Hosp, Dept Gastroenterol, Townsville, Qld, Australia

[6] Austin Hlth, Dept Gastroenterol, Melbourne, Vic, Australia

[7] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[8] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic, Australia

[9] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[10] St Vincents Hosp, Dept Gastroenterol, Sydney, NSW, Australia

[11] Liverpool Hosp, Dept Gastroenterol, Sydney, NSW, Australia

[12] Flinders Med Ctr, Dept Gastroenterol, Adelaide, SA, Australia

[13] Royal Adelaide Hosp, Dept Gastroenterol, Adelaide, SA, Australia

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2017年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：142 / 142

页数：1

共 50 条

[11] Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center
Hoffmann, Peter
Krisam, Johannes
Stremmel, Wolfgang
Gauss, Annika
[J]. DIGESTIVE DISEASES, 2019, 37 (01) : 33 - 44
[12] Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, Brian G.
Rutgeerts, Paul
Sands, Bruce E.
Hanauer, Stephen
Colombel, Jean-Frederic
Sandborn, William J.
Van Assche, Gert
Axler, Jeffrey
Kim, Hyo-Jong
Danese, Silvio
Fox, Irving
Milch, Catherine
Sankoh, Serap
Wyant, Tim
Xu, Jing
Parikh, Asit
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 699 - 710
[13] Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis A single-center experience in Northern China
Yan, Jing
Ding, Xueli
Wu, Jun
Liu, Ailing
Fang, Liang
Xu, Yonghong
[J]. MEDICINE, 2024, 103 (27)
[14] Letter: real-life management of new onset ulcerative colitis and proctitis
Domenech, E.
Gisbert, J. P.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (07) : 685 - 686
[15] Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis
Pugliese, Daniela
Armuzzi, Alessandro
[J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (01) : 11 - 12
[16] Real World Experience With Vedolizumab as First-Line Therapy for the Treatment of Ulcerative Colitis
Ritter, Timothy E.
Mehta, Samantha A.
Van Anglen, Lucinda J.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S439 - S439
[17] OUTCOMES OF ANTI-TNF VERSUS VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: THE LEEDS EXPERIENCE
Johnston, A. J.
Lenti, M.
O'Connor, A.
Selinger, C.
Ford, A. C.
Hamlin, P. J.
[J]. GUT, 2017, 66 : A152 - A152
[18] Outcomes of anti-TNF versus Vedolizumab therapy for ulcerative colitis: the Leeds experience
Lenti, M. V.
Johnston, A.
O'Connor, A.
Selinger, C.
Ford, A. C.
Hamlin, P. J.
[J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S192 - S193
[19] VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS
Thurston, Theresa
Moskow, Joshua
Glassner, Kerri
Abraham, Bincy
[J]. INFLAMMATORY BOWEL DISEASES, 2023, 29 : S81 - S81
[20] VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS
Thurston, Theresa
Moskow, Joshua
Glassner, Kerri
Abraham, Bincy
[J]. GASTROENTEROLOGY, 2023, 164 (04) : S104 - S104

← 1 2 3 4 5 →